<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799564</url>
  </required_header>
  <id_info>
    <org_study_id>MPL4DRY</org_study_id>
    <nct_id>NCT01799564</nct_id>
  </id_info>
  <brief_title>Micropulse Laser for Geographic Atrophy</brief_title>
  <acronym>MPL4DRY</acronym>
  <official_title>A Phase I Study to Establish the Safety and Efficacy of Retinal Pigment Epithelium Micropulse Laser in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de la Macula y la Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de la Macula y la Retina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Geographic atrophy (GA) causes the loss of the retinal pigment epithelium (RPE) cells in
      broad areas of the retina. The application of subthreshold micropulse laser spots in healthy
      RPE in the vicinity of the area of GA may restore the imbalance in survival factors caused by
      the disease (ie, the laser may decrease vascular endothelial growth factor and RPE-derived
      transforming growth factor beta, upregulation of pigment epithelium-derived factor). This may
      slow or even stop the enlargement of atrophy secondary to GA, and therefore, avoid further
      vision loss.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in area of atrophy as measured with fundus autofluorescence</measure>
    <time_frame>Change in area from baseline to week 48</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Micropulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The fellow eye does not receive any treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Micropulse</intervention_name>
    <description>Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye</description>
    <arm_group_label>Micropulse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GA &gt; 0.5 disk areas secondary to AMD in both eyes

          -  50 years or older

          -  The periphery of the atrophic lesions must demonstrate increased autofluorescence

          -  Best corrected visual acuity between 20/20 and 20/400 inclusive

          -  Clear ocular media

          -  Ability to provide informed consent and attend all study visits

        Exclusion Criteria:

          -  GA secondary to other causes aside from AMD

          -  Evidence of choroidal neovascularization in either eye

          -  Any prior treatment for AMD, aside from antioxidants

          -  Any other ocular condition that would progress in the study period and confound visual
             acuity assessment

          -  Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve

          -  Presence of idiopathic or autoimmune-associated uveitis

          -  Any intraocular surgery 3 months of entry

          -  Any prior thermal laser in the macula

          -  History of vitrectomy, filtering surgery, corneal transplant or retinal detachment
             surgery

          -  Previous therapeutic radiation in the ocular region in either eye

          -  Any treatment with an investigational agent in the previous 60 days before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Monés, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de la màcula i de la retina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Monés, MD, PhD</last_name>
    <phone>+34935950155</phone>
    <email>info@institutmacularetina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Biarnés, OD, MPH</last_name>
    <phone>+34935950155</phone>
    <email>marcb@institutmacularetina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de la màcula i de la retina</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Biarnés, OD, MPH</last_name>
      <phone>+34.935950155</phone>
      <email>marcmbp@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de la Macula y la Retina</investigator_affiliation>
    <investigator_full_name>Jordi Mones</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Geographic atrophy</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Fundus autofluorescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

